Sheng J, Zhang X, Liang W, Lyu J, Zhang B, Min J
BMC Biol. 2025; 23(1):69.
PMID: 40038674
PMC: 11881384.
DOI: 10.1186/s12915-025-02175-1.
Hoseinzadeh A, Esmaeili S, Sahebi R, Melak A, Mahmoudi M, Hasannia M
Stem Cell Res Ther. 2025; 16(1):33.
PMID: 39901306
PMC: 11792531.
DOI: 10.1186/s13287-025-04158-z.
Liu Y, Xu L, Dou Y, He Y
Mol Cancer. 2025; 24(1):11.
PMID: 39799359
PMC: 11724481.
DOI: 10.1186/s12943-024-02210-9.
Naidoo K, Altfeld M
Viruses. 2024; 16(10).
PMID: 39459918
PMC: 11512232.
DOI: 10.3390/v16101584.
Nicolini A, Ferrari P
Front Immunol. 2024; 15:1353787.
PMID: 39119332
PMC: 11306065.
DOI: 10.3389/fimmu.2024.1353787.
In-depth analysis of the interplay between oncogenic mutations and NK cell-mediated cancer surveillance in solid tumors.
Pesini C, Artal L, Paul Bernal J, Sanchez Martinez D, Pardo J, Ramirez-Labrada A
Oncoimmunology. 2024; 13(1):2379062.
PMID: 39036370
PMC: 11259085.
DOI: 10.1080/2162402X.2024.2379062.
Purine metabolite inosine induced by transforming growth factor‑β promotes epithelial‑mesenchymal transition in colorectal cancer.
Hu W, Cheng L, Zhao J, Wu Y, Lin Y, Yin J
Oncol Lett. 2024; 28(3):416.
PMID: 38988443
PMC: 11234247.
DOI: 10.3892/ol.2024.14549.
TGF-β: an active participant in the immune and metabolic microenvironment of multiple myeloma : TGF-β in the microenvironment of multiple myeloma.
Xue H, Wei F
Ann Hematol. 2024; 103(11):4351-4362.
PMID: 38900304
PMC: 11534828.
DOI: 10.1007/s00277-024-05843-4.
TGF-β blockade drives a transitional effector phenotype in T cells reversing SIV latency and decreasing SIV reservoirs in vivo.
Kim J, Bose D, Arainga M, Haque M, Fennessey C, Caddell R
Nat Commun. 2024; 15(1):1348.
PMID: 38355731
PMC: 10867093.
DOI: 10.1038/s41467-024-45555-x.
Charting a killer course to the solid tumor: strategies to recruit and activate NK cells in the tumor microenvironment.
Portillo A, Monteiro J, Rojas E, Ritchie T, Gillgrass A, Ashkar A
Front Immunol. 2023; 14:1286750.
PMID: 38022679
PMC: 10663242.
DOI: 10.3389/fimmu.2023.1286750.
Engineering the glioblastoma microenvironment with bioactive nanoparticles for effective immunotherapy.
Blanchard R, Adjei I
RSC Adv. 2023; 13(45):31411-31425.
PMID: 37901257
PMC: 10603567.
DOI: 10.1039/d3ra01153d.
p35 is a Crucial Player in NK-cell Cytotoxicity and TGFβ-mediated NK-cell Dysfunction.
Wong D, Fritz C, Feinberg D, Huang A, Parameswaran R
Cancer Res Commun. 2023; 3(5):793-806.
PMID: 37377891
PMC: 10162136.
DOI: 10.1158/2767-9764.CRC-22-0497.
Immunometabolic reprogramming, another cancer hallmark.
Kumar V, Stewart 4th J
Front Immunol. 2023; 14:1125874.
PMID: 37275901
PMC: 10235624.
DOI: 10.3389/fimmu.2023.1125874.
Regulation of short-chain fatty acids in the immune system.
Liu X, Shao J, Liao Y, Wang L, Jia Y, Dong P
Front Immunol. 2023; 14:1186892.
PMID: 37215145
PMC: 10196242.
DOI: 10.3389/fimmu.2023.1186892.
Transforming Growth Factor-β1 in Cancer Immunology: Opportunities for Immunotherapy.
Villar V, Suboticki T, dikic D, Mitrovic-Ajtic O, Simon F, Santibanez J
Adv Exp Med Biol. 2023; 1408:309-328.
PMID: 37093435
DOI: 10.1007/978-3-031-26163-3_17.
Butyrate limits human natural killer cell effector function.
Zaiatz-Bittencourt V, Jones F, Tosetto M, Scaife C, Cagney G, Jones E
Sci Rep. 2023; 13(1):2715.
PMID: 36792800
PMC: 9932090.
DOI: 10.1038/s41598-023-29731-5.
Metabolic regulation of NK cell function: implications for immunotherapy.
Sohn H, Cooper M
Immunometabolism (Cobham). 2023; 5(1):e00020.
PMID: 36710923
PMC: 9869966.
DOI: 10.1097/IN9.0000000000000020.
Inflammatory-driven NK cell maturation and its impact on pathology.
Bourayou E, Golub R
Front Immunol. 2022; 13:1061959.
PMID: 36569860
PMC: 9780665.
DOI: 10.3389/fimmu.2022.1061959.
Preventing Surgery-Induced NK Cell Dysfunction Using Anti-TGF-β Immunotherapeutics.
Market M, Tennakoon G, Scaffidi M, Cook D, Angka L, Ng J
Int J Mol Sci. 2022; 23(23).
PMID: 36498937
PMC: 9737532.
DOI: 10.3390/ijms232314608.
Natural Killer Cells in Chronic Lymphocytic Leukemia: Functional Impairment and Therapeutic Potential.
Yano M, Byrd J, Muthusamy N
Cancers (Basel). 2022; 14(23).
PMID: 36497266
PMC: 9739887.
DOI: 10.3390/cancers14235787.